

## Annual Flash Report (unaudited)

Fiscal Year ended March 31, 2016

### Sales of Major Products

Supplemental Data

For information purpose only

		Hundreds of Millions of yen					
		Year ended March 31, 2016			Year ending March 31, 2017		
		Results	Increase/Decrease		Forecast	Increase/Decrease	
<b>Opdivo</b>	Agent for treatment of unresectable melanoma and unresectable, advanced or recurrent non-small cell lung cancer	¥ 212	¥ +186	+741.0 %	¥ 1,260	¥ +1,048	+495.7 %
<b>Glactiv</b>	Agent for type II diabetes	314	+6	+2.1 %	295	△ 19	△ 6.1 %
<b>Opalmon</b>	Circulatory system agent	227	△ 21	△ 8.6 %	175	△ 52	△ 22.9 %
<b>Recalbon</b>	Agent for osteoporosis	113	+10	+9.9 %	115	+2	+1.8 %
<b>Forxiga</b>	Agent for type II diabetes	43	+27	+177.3 %	100	+57	+134.0 %
<b>Orencia SC</b>	Agent for rheumatoid arthritis	80	+39	+93.7 %	100	+20	+24.8 %
<b>Emend/Proemend</b>	Agent for Chemotherapy-induced nausea and vomiting	95	+9	+10.2 %	100	+5	+5.6 %
<b>Rivastach</b>	Agent for Alzheimer's disease	78	+11	+15.6 %	90	+12	+14.9 %
<b>Onon</b>	Agent for bronchial asthma and allergic rhinitis	90	△ 13	△ 12.6 %	65	△ 25	△ 27.4 %
<b>Onoact</b>	Agent for tachyarrhythmia during and post operation	57	+10	+22.4 %	65	+8	+13.9 %
<b>Staybla</b>	Agent for overactive bladder (pollakiuria and urinary incontinence)	52	△ 1	△ 1.9 %	50	△ 2	△ 3.2 %
<b>Onon dry syrup</b>	Agent for pediatric bronchial asthma and allergic rhinitis	56	△ 2	△ 3.2 %	45	△ 11	△ 19.7 %
<b>Foipan</b>	Agent for chronic pancreatitis and postoperative reflux esophagitis	52	△ 9	△ 15.1 %	40	△ 12	△ 22.4 %
<b>Kinedak</b>	Agent for diabetic peripheral neuropathy	41	△ 7	△ 14.6 %	30	△ 11	△ 26.6 %
<b>Elaspol</b>	Agent for acute lung injury associated with SIRS	17	△ 9	△ 34.7 %	10	△ 7	△ 42.8 %

Note: Sales of products are shown in a gross sales basis.